Larimar Therapeutics, Inc.

NasdaqGM:LRMR 주식 보고서

시가총액: US$493.9m

Larimar Therapeutics 관리

관리 기준 확인 3/4

Larimar Therapeutics CEO는 Carole Ben-Maimon, May2020 에 임명되었습니다 의 임기는 4.5 년입니다. 총 연간 보상은 $ 3.14M, 17.8% 로 구성됩니다. 17.8% 급여 및 82.2% 보너스(회사 주식 및 옵션 포함). 는 $ 875.22K 가치에 해당하는 회사 주식의 0.18% 직접 소유합니다. 875.22K. 경영진과 이사회의 평균 재임 기간은 각각 4.3 년과 4.3 년입니다.

주요 정보

Carole Ben-Maimon

최고 경영자

US$3.1m

총 보상

CEO 급여 비율17.8%
CEO 임기4.5yrs
CEO 소유권0.2%
경영진 평균 재임 기간4.3yrs
이사회 평균 재임 기간4.3yrs

최근 관리 업데이트

Recent updates

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Oct 07

Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans

Aug 09
Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans

Larimar Therapeutics: More Data Still Needed

Jul 15

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

May 31

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Nov 13
We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

May 19
Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 02
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Laramar Therapeutics issued patent for lead pipeline candidate

Oct 20

Larimar Therapeutics prices ~$70M stock offering

Sep 14

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Sep 02
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Larimar Therapeutics GAAP EPS of -$0.47

Aug 11

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Mar 21
We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Dec 18
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Larimar under pressure as FDA puts clinical hold on CTI-1601 program

May 26

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 08
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Larimar, Avadel, Applied Therapeutics will added to Nasdaq Biotechnology Index

Dec 15

Larimar completes dosing in Friedreich’s Ataxia, provides program update

Dec 08

Larimar Therapeutics (LRMR) Investor Presentation - Slideshow

Nov 16

Larimar Therapeutics reports Q3 results

Nov 10

CEO 보상 분석

Carole Ben-Maimon 의 보수는 Larimar Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$65m

Jun 30 2024n/an/a

-US$58m

Mar 31 2024n/an/a

-US$45m

Dec 31 2023US$3mUS$560k

-US$37m

Sep 30 2023n/an/a

-US$33m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$2mUS$528k

-US$35m

Sep 30 2022n/an/a

-US$35m

Jun 30 2022n/an/a

-US$44m

Mar 31 2022n/an/a

-US$47m

Dec 31 2021US$2mUS$510k

-US$51m

Sep 30 2021n/an/a

-US$56m

Jun 30 2021n/an/a

-US$49m

Mar 31 2021n/an/a

-US$48m

Dec 31 2020US$5mUS$268k

-US$42m

보상 대 시장: Carole 의 총 보상 ($USD 3.14M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 2.40M ).

보상과 수익: 회사가 수익성이 없는 동안 Carole 의 보상이 증가했습니다.


CEO

Carole Ben-Maimon (65 yo)

4.5yrs

테뉴어

US$3,137,432

보상

Dr. Carole S. Ben-Maimon, M.D., is President, Chief Executive Officer and Director at Larimar Therapeutics, Inc. since May 28, 2020. She was Chief Executive Officer, President and Director at Chondrial The...


리더십 팀

이름위치테뉴어보상소유권
Carole Ben-Maimon
CEO, President & Director4.5yrsUS$3.14m0.18%
$ 875.2k
Michael Celano
Secretary & CFO4.5yrsUS$1.42m0.087%
$ 431.5k
Gopi Shankar
Chief Development Officer1.8yrsUS$1.43m0.0078%
$ 38.7k
John Berman
Vice President of Finance & Administration1.3yrs데이터 없음데이터 없음
Jennifer Johansson
Vice President of Legal & Compliance7.9yrs데이터 없음데이터 없음
Russell Clayton
Chief Medical Officer1.3yrs데이터 없음데이터 없음
Francis Conway
VP & Controller4.3yrs데이터 없음데이터 없음

4.3yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 관리: LRMR 의 관리팀은 경험 ( 4.3 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
Carole Ben-Maimon
CEO, President & Director4.5yrsUS$3.14m0.18%
$ 875.2k
Jonathan Leff
Independent Director4.5yrsUS$79.96k데이터 없음
Jeffrey Sherman
Independent Director1.1yrsUS$56.43k0%
$ 0
Frank Thomas
Independent Director10.4yrsUS$86.21k0.0031%
$ 15.5k
Thomas Hamilton
Independent Director4.5yrsUS$77.77k0.89%
$ 4.4m
Joseph Truitt
Independent Chairman of the Board4.5yrsUS$114.96k0.0043%
$ 21.3k
Giovanni Manfredi
Member of Scientific Advisory Board4.1yrs데이터 없음데이터 없음
Mark Payne
Member of Scientific Advisory Board4.1yrs데이터 없음데이터 없음
Marni Falk
Member of Scientific Advisory Board4.1yrs데이터 없음데이터 없음
Jill Ostrem
Member of Scientific Advisory Board2.2yrs데이터 없음데이터 없음

4.3yrs

평균 재임 기간

57.5yo

평균 연령

경험이 풍부한 이사회: LRMR 의 이사회경험(평균 재직 기간 4.3 년)으로 간주됩니다.